3D Medicines Inc

3D Medicines Inc is a Shanghai-based commercial-stage biopharmaceutical company focused on developing and commercializing next-generation immuno-oncology therapies for cancer patients. Its lead product is envafolimab (ENWEIDA), a subcutaneous PD-L1 antibody approved in China in 2021 for previously treated MSI-H/dMMR advanced solid tumors. The company is listed on the Hong Kong Stock Exchange under stock code 1244.HK.